Despite the new studies, other groups have shown that the combined use of RBN-2397 together with ARH pathway agonists (target described for PARP7), shows great effectiveness on various tumor lines of colon, lung, kidney, breast, or melanoma, manifesting a clear mechanism of synthetic lethality; a very promising study and of great clinical relevance [74,95]. Here, TIPARP is linked to neoplasm.